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Icariside II (ICS II) is a broad-spectrum anti-cancer natural compound extracted
from Herba Epimedii Maxim. Recently, the role of ICS II has been investigated
in central nervous system, especially have a neuroprotective effect in Alzheimer’s
disease (AD). In this study, we attempted to investigate the effects of ICS II, on
cognitive deficits and beta-amyloid (Aβ) production in APPswe/PS1dE9 (APP/PS1)
double transgenic mice. It was found that chronic ICS II administrated not
only effectively ameliorated cognitive function deficits, but also inhibited neuronal
degeneration and reduced the formation of plaque burden. ICS II significantly
suppressed Aβ production via promoting non-amyloidogenic APP cleavage process
by up-regulating a disintegrin and metalloproteinase domain 10 (ADAM10) expression,
inhibited amyloidogenic APP processing pathway by down-regulating amyloid precursor
protein (APP) and β-site amyloid precursor protein cleavage enzyme 1 (BACE1)
expression in APP/PS1 transgenic mice. Meanwhile, ICS II attenuated peroxisome
proliferator-activated receptor-γ (PPARγ) degradation as well as inhibition of eukaryotic
initiation factor α phosphorylation (p-eIF2α) and PKR endoplasmic reticulum regulating
kinase phosphorylation (p-PERK). Moreover, phosphodiesterase type 5 inhibitors
(PDE5-Is) have recently emerged as a possible therapeutic target for cognitive
enhancement via inhibiting Aβ levels, and we also found that ICS II markedly
decreased phosphodiesterase-5A (PDE5A) expression. In conclusion, the present study
demonstrates that ICS II could attenuate spatial learning and memory impairments in
APP/PS1 transgenic mice. This protection appears to be due to the increased ADAM10
expression and decreased expression of both APP and BACE1, resulting in inhibition
of Aβ production in the hippocampus and cortex. Inhibition of PPARγ degradation and
PERK/eIF2α phosphorylation are involved in the course, therefore suggesting that ICS II
might be a promising potential compound for the treatment of AD.
Keywords: icariside II, Alzheimer’s disease, beta-amyloid, a disintegrin and metalloproteinase domain 10, beta-
site APP cleavage enzyme 1, peroxisome proliferator-activated receptor-γ
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INTRODUCTION
Alzheimer’s disease is the most common age-related
neurodegenerative disorder. Its primary clinical symptom
is progressive cognitive function deterioration, such as impaired
communication, confusion, and poor judgment (Alzheimer’s
Association, 2015). It is estimated that as many as 46.8 million
people worldwide are suffering from dementia in 2015 and the
number of AD patients rises by more than 11 million people per
year, which leads to a tremendous burden on the society and
the family (Carrillo et al., 2013; Alzheimer’s Association, 2015).
Clinically, the hallmarks of AD include the deposition of senile
plaques, which are comprised of Aβ peptides neurofibrillary
tangles (NFTs), and the death of neurons accompanied by
synapses loss (Yang R.Y. et al., 2015). Although the pathogenesis
of AD is complicated and the mechanisms governing this disease
remains elusive, extensive studies suggest that Aβ cascade
hypothesis remains dominating the AD research, which centers
on Aβ as the most critical initiator in the pathogenesis of AD
(Sun et al., 2015; Sengupta et al., 2016). Aβ results from the
sequential proteolytic processing of APP by BACE1 (as the
rate-limiting secretase) and γ-secretase, the cleavage step is
contributes much to AD pathology (Zhang and Song, 2013).
However, in the non-amyloidogenic cleavage process, APP
is cleaved by α-secretase (a large metallopeptidase family,
known as ADAM) to produce non-toxic fragments, which is
deemed to antagonize Aβ generation (Vassar, 2013; Sun et al.,
2015). Excessive accumulation and aggregation of Aβ result
in neurotoxicity in the nervous system, inducing neuronal
degeneration and eventually the death of neurons (Zhu et al.,
2013), which further causes memory deficits (Sun et al., 2015).
Currently clinical available pharmacotherapies of AD include
acetylcholinesterase inhibitors (such as donepezil, tacrine,
rivastigmine, and galantamine) and N-methyl-D-aspartate
receptor antagonists (memantine) (Fan and Chiu, 2014). Given
that the etiology of AD is multiple, these agents only ameliorate
certain symptoms but do not change or delay the progress of AD
which substantially limits their clinical utilities (Anand et al.,
2013). Thus, new therapies for AD are in dire need.
Among numerous therapeutic strategies of AD, BACE1 has
always attracted much attention to investigate it’s biological
function on APP-Aβ process. Increasing evidence indicated that
BACE1 overexpression and Aβ accumulation were observed in
brains of AD mouse models and patients. However, Aβ and
β-secretase-cleaved APP fragments were decreased in BACE1-
knockdown model mice (Sankaranarayanan et al., 2008). Thus,
the relationship between BACE1 and Aβ production has explicitly
point out that screening out compound for decreasing BACE1
level for against AD. But to date, majority of compounds that
Abbreviations: Aβ, beta-amyloid; AD, Alzheimer’s disease; ADAM10, a disintegrin
and metalloproteinase domain 10; APP, amyloid precursor protein; APP/PS1,
APPswe/PS1dE9; BACE1, β-site APP cleavage enzyme 1; eIF2α, eukaryotic
initiation factor α; ICS II, icariside II; MWM, Morris water maze; NFTs,
neurofibrillary tangles; NS, normal saline; PBS, phosphate buffer saline; PDE5-Is,
phosphodiesterase type 5 inhibitors; PDE5A, phosphodiesterase type 5A; PERK,
PKR endoplasmic reticulum regulating kinase; PPARγ, peroxisome proliferator-
activated receptor-γ; sAPPα, soluble APP-α; sAPPβ, soluble APP-β; WT, wild
type.
inhibiting BACE1 still exist many side effects in clinical trials
(including peptides and synthetic). Several natural compounds
isolated from Chinese medical herbs, such as ginsenoside,
because of its pharmacological safety and therapeutic potential,
which are widely applied in prophylaxis and treatment of various
illness (Yang X.-D. et al., 2015; Cao et al., 2016; Xie et al., 2016).
Herba Epimedium is a popular Chinese medicinal plant,
traditionally used as cardiovascular diseases and cancer
therapy (Sze et al., 2010). One of its bioactive flavonoid
compounds, ICS II, shows good CNS penetration and robust
biological activities. ICS II protect against cerebral ischemia
reperfusion injury in rats via an integrated mechanism of
nuclear factor-κB inhibition and peroxisome proliferator
activated receptor up-regulation (Deng et al., 2016). Similarly,
ICS II alleviates hippocampal injury in a gerbil model of
ischemia-reperfusion (Yan et al., 2014). In addition, our previous
research has shown that ICS II attenuates streptozotocin-
induced cognitive deficits and neuronal degeneration, the
level of Aβ contents are also decreased in rats, the underlying
mechanisms of which may be associated with the inhibition
of BACE1 level (Zhang and Song, 2013; Yin et al., 2016).
However, it is unclear whether ICS II could ameliorate
cognitive function impairments via inhibiting multiple
pathogenic pathways of Aβ production in APP/PS1 transgenic
mice.
In this study, APP/PS1 transgenic mice were utilized to
examine whether chronic treatment of ICS II could improve
spatial learning and ameliorate memory impairments. We also
examined the underlying biochemical mechanisms related to
the behavioral changes. Here we show that ICS II effectively
ameliorated cognitive functions deficits via inhibiting neuronal
loss and the formation of senile plaques, at least partly, by
decreasing Aβ production.
MATERIALS AND METHODS
Reagents
Icariside II ≥98% by (HPLC), which was provided from Nanjing
Zelang Medical Technology Corporation Ltd (China). All related
experiment reagents were reagent grade and commercially
available.
Animals
All male APPswe/PS1dE9 transgenic model mice (APP/PS1) and
their littermates WT mice (weighing 30–35 g) were obtained
from the Model Animal Research Centre of Nanjing University.
Mice were allowed to acclimatize under SPF-class animal
housing of laboratory (certificate no. SYXK 2011-004) at Zunyi
Medical University, with 12 h light/dark cycle, temperature
(22 ± 1◦C), relative humidity (60–70%), food and drinking
water were available ad libitum. Animal experiments were strictly
implemented according to the State Committee of Science and
Technology of the People’s Republic of China Order No. 2 on
November 14, 1988 (revised 2011) and the protocols in this study
were allowed by the Animal Experimentation Ethics Committee
of the Zunyi Medical University.
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Animal Treatments
Nine-month-old male APP/PS1 transgenic mice were
randomized divided into three groups: ICS II treated groups
(10 mg/kg, n = 12; 30 mg/kg, n = 13) and APP/PS1 control
group (n = 12). Age-matched male WT mice were randomized
assigned to three groups: ICS II treated groups (10 and 30 mg/kg,
n = 10) and WT control group (n = 10). APP/PS1 and WT
treated groups were orally administered with ICS II dissolved in
NS at a dose of 10, 30 mg/kg body weight once daily, and control
groups received volume-matched NS for 3 months.
Morris Water Maze (MWM) Test
After 3 months of treatment, MWM task was applied to
evaluate cognitive abilities of the mice (under the condition of
experimenters blinded to the treatments). In brief, the apparatus
consisted of a circular white plastic water tank (the diameter was
120 cm and height was 50 cm) and filled with water (24 ± 1◦C)
to a depth of 30 cm, the area of tank was divided into four
quadrants of equal size, a removable circular platform of perspex
(9.5 cm diameter, 29 cm height) was hidden in the midpoint of
the third quadrant and submerged 1 cm beneath the surface of
water for all trials and sessions. Spatial acquisition ability was
measured during four consecutive days, during which the mouse
was released into the water that one of the four quadrants and
allowed 60 s to reach the hidden platform and keep on it for
20 s, and the escape latency (swim toward the hidden platform
and keep on it for more than 3 s) were recorded. If mice failed
to found the hidden platform within preset time (the escape
latency was recorded as 60 s), and it would be softly guided to
the hidden platform where it remained on top of the platform
for 20 s. Per mouse was experimented to four trials per day and
the inter-trial interval was 20 min. A probe trial was performed
in the fifth day to measure the final spatial memory consolidation
(hidden platform was withdrawn). The percentage of time of each
mouse was recorded during a 60 s trial. These activities in all trials
were automatically measured and analyzed by using the behavior
analyzing system (TopScan Version 3.00).
Tissue Preparation
All animals were deeply anesthetized with sodium pentobarbital
(50 mg/kg intraperitoneally) after MWM test, and mice
(n= 4–5 per group) were perfused transcardially with ice-cold
0.01M phosphate-buffered saline (PBS, pH = 7.4), followed by
the precooled 4% buffered paraformaldehyde (pH = 7.4), then
the brain was instantly removed and stored in fresh fixative at
4◦C overnight. The right hemispheres of brains were dehydrated
through the gradient of 20 and 30% sucrose solutions until
sank at 4◦C. The respective left hemispheres were embedded by
paraffin. For other animals (n= 6–8 per group), the hippocampus
and cortex were immediately isolated and stored at −80◦C with
Eppendorf micro test tubes.
Thioflavine S and Nissl Staining
The right hemispheres of brains were serially cut using a cryostat
(Leica CM 1850 UV; Leica, Nussloch, Germany) at 30 µm
thickness sections in the coronal plane. The brain slices were
collected sequentially in 24-well plates, which filling with anti-
freezing solution and stored at−20◦C. To observe the formation
of senile plaques in hippocampus of mice, the brain slices
were placed in a 1% thioflavine S (Lot# SLBG4212V, Sigma,
USA) for 10 min, and then eluted with 70% alcohol, and
finally washed with PBS three times and mounted with glycerin
jelly, with all of the steps carefully kept away from light. The
green fluorescence-tagged senile plaques were examined under
a fluorescence microscope (BX53+DP80, Olympus, Japan). The
numbers of senile plaques in the hippocampus were counted
by Image-Pro Plus (Media Cybernetics, Bethesda, MD, USA).
Meanwhile, the left hemispheres of brains fixed with fresh
4% paraformaldehyde solution for 1 week at 4◦C, Finally,
the samples were embedded in paraffin. Three-micrometer-
thick brain tissue coronal sections of mice were stained with
toluidine blue (Solarbio, China). The Nissl bodies were stained
blue-purple in the CA3 and DG regions of hippocampus.
The morphological changes (normal neurons having granular
cytoplasm and euchromatic nucleus with large nucleoli) were
observed under a light microscope (KS300, Zeiss-Kontron,
Germany). Viable neurons in the CA3 and DG region of
hippocampus from each group were counted as previously
described (Liu et al., 2015).
Western Blot Analysis
Hippocampus and cortex tissues (n = 3–4 per group) were
homogenized at 4◦C in the radio-immunoprecipitation (RAPI)
assay lysis buffer containing complete protease inhibitor mixture
by using a plastic homogenizer and then sonicated for 30 min
on an ice plate. The homogenized tissue were centrifuged for
15 min (12000 × g, 4◦C), and supernatant was extracted and
subpackaged, finally stored at−80◦C. The concentrations of total
protein were tested by BCA protein assay kit (Beyotime, China),
and equal amounts of protein (approximately 25 or 30 µg) were
heat-denatured at 100◦C for 5 min, electrophoretically separated
using 6–12% SDS-PAGE gels, electrophoretic transferred onto
the PVDF membranes (0.45 µm). Membranes were then
blocked with 2% BSA or 5% defatted in 1 × TBST for 1–
3 h and next probed with corresponding primary antibodies
against APP (1:1,000, AB60097b, BBB Life sciences, USA),
Aβ1−40 (1:1,000, MAB2675, Abnova, USA), Aβ1−42 (1:1,000,
#14974, CST, USA), PDE5A1 (1:1,000, ab14672, Abcam, USA),
sAPPα (2B3) (1:500, Immuno-Biological Laboratories, USA),
ADAM10 (1:500, ab124695, Abcam, USA), sAPPβ (6A1)
antibody (1:500, Immuno-Biological Laboratories, USA), BACE1
(1:1,000, ab108394, Abcam, USA), PPARγ (1:500, ab19481,
Abcam, USA), p-PERK (Thr981) (1:200, sc-32577, Santa Cruz
Biotechnology, USA), total PERK (1:200, sc-13073, Santa
Cruz Biotechnology, USA), p-eIF2α (Ser51) (1:200, ab32157,
Abcam, USA), total eIF2α (1:500, ab5369, Abcam, USA), and
β-actin (1:2,000, AA128, Beyotime, China) overnight at 4◦C.
After incubation with appropriate HRP-conjugated secondary
antibodies for 1–2 h at room temperature, the immunoreactive
protein was exhibited with ECL detection reagent (Beyotime,
China) and the densitometry of band was analyzed using
Quantity One-4.6.7. (Bio-Rad, USA).
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Statistics
The data were presented as mean ± SEM. All statistical
analyses were performed using SPSS software, version 17.0 (SPSS,
Chicago, IL, USA). MWM task data were analyzed using repeated
measures analysis of variance (ANOVA). Firstly, Mauchly’s test of
sphericity should be used to judge whether there were relations
among the repeatedly measured data. If any (P < 0.05), and
the Greenhouse-Geisser corrected results should be taken. With
multivariate ANOVA, date in different treated group of each
measurement time could be compared pairwise.
For the data that did not involve repeated measures, they were
analyzed using one-way ANOVA. If the ANOVA test results were
significant, the individual differences among different groups
or conditions were determined by post hoc least significant
difference (LSD). A probability value of <0.05 was statistically
considered significant differences.
RESULTS
Effects of ICS II on Spatial Learning and
Memory in APP/PS1 Transgenic Mice
To investigate the effects of ICS II on cognitive deficits in
APP/PS1 transgenic mice, the spatial learning and memory of
all mice were evaluated through the MWM. The P-value of
Mauchly’s Test of Sphericity in escape latency was less than 0.05
(P = 0.017), which did not accept the sphericity assumption.
Then the Greenhouse-Geisser correction was used, and the main
effect of “latency between days” and “latency between groups”
was significant difference [F(2.619,157.127) = 55.309, p < 0.001]
and [F(5,60) = 2.912, p = 0.02], respectively. The interaction
of “days × groups” was no significant [F(13.094,157.127) = 1.520,
p= 0.115]. During the consecutive 5 days of training, acquisition
ability of spatial learning and memory were measured (Figure 1).
In the navigation test, as illustrated in Figure 1B, the escape
latency of all mice was gradually shortened and their ability to
locate the platform was improved with the training. On days
2–4 (Figure 1B), APP/PS1 transgenic mice showed increased
mean escape latencies (p < 0.05). With the chronic treatment
with ICS II at the dose of 30 mg/kg, no obvious differences in
mean escape latencies were observed on the first and second
days compared with APP/PS1 control group, while notable
differences were detected on the third and fourth days (p < 0.05,
p < 0.05, respectively). Interestingly, on days 2–3, the mean
escape latencies were reduced after treatment with ICS II at the
dose of 10 mg/kg for 3 months (p < 0.05, p < 0.01, respectively).
But there was no noticeable change on day 4 (p> 0.05).
The percentage of time that animals spent in the target
quadrant during the search for the platform in probe trial is
shown in Figure 1C. There was a very low percentage on time
spent in target quadrant in APP/PS1 control group (p < 0.01)
[F(5,60) = 6.860, p < 0.001], indicative of cognitive function
deficits. Nevertheless, ICS II (10 mg/kg) treated group spent more
time in the target quadrant (p< 0.01). Similar effect was observed
at a larger dose of ICS II (30 mg/kg) (p < 0.01). In addition, the
swimming speed did not show significant differences among the
groups, suggesting that ICS II treatment did not affect the motor
ability in mice. Together, these results indicated that chronic
treatment of ICS II could ameliorate the spatial learning and
memory impairments in APP/PS1 transgenic mice.
The Effects of ICS II on Neuronal Cells in
the Hippocampus of APP/PS1
Transgenic Mice
The viable neuron is believed to be an especially important role
in the learning and memory functions. Therefore, the number
of neuronal cells in the CA3 and DG regions of hippocampus
were evaluated to investigate the effects of ICS II treatment on
the neuronal morphology change by Nissl staining. As the shown
in Figure 2A, normal morphological features of pyramidal cells
is intact structure, including granular cytoplasm and whereas
the apparent pathological changes with loosely arranged neurons
and less neurons were found in APP/PS1 transgenic mice
hippocampal CA3 and DG regions, viable neurons were counted
using three equally spaced coronal sections passing through
the hippocampus for each brain [F(5,12) = 3.359, p = 0.04;
F(5,12) = 4.975, p = 0.011] (p < 0.05; p < 0.01) (Figures 2B,C).
The mean numbers of neurons were clearly more with ICS II
treatment than controls (p < 0.05; p < 0.05). Overall, these data
demonstrated that ICS II attenuated neuronal death in APP/PS1
transgenic mice.
Effects of ICS II on Senile Plaque
Formation in the Hippocampus of
APP/PS1 Transgenic Mice
In the brain of AD patients, the most remarkable
neuropathological feature is Aβ overproduction, which
ultimately causes the formation of senile plaque. In the
present study, we evaluated the effects of ICS II on the formation
of senile plaque in coronal sections of hippocampus from
different groups (Figure 2D). Senile plaque formation was
not found in WT mice at the age of 12 months, in contrast,
thioflavine S staining revealed the presence of extensive senile
plaques in the hippocampus of age-matched APP/PS1 transgenic
mice. Importantly, quantification analysis exhibited that the
amyloid burden (% of total areas) was remarkably reversed
by ICS II [F(2,6) = 9.116, p = 0.015] (p < 0.01) (Figure 2E),
whereas was not found difference in low dose of ICS II 10 mg/kg.
Simultaneously, the number of amyloid plaque was significantly
decreased in APP/PS1 transgenic mice treated with ICS II
(10 mg/kg) when compared with APP/PS1 transgenic mice
[F(2,6) = 3.618, p = 0.093] (p < 0.05) (Figure 2F). Taken
together, these results suggested an inhibitory effect of ICS II on
amyloid plaque formation.
Effects of ICS II on the Levels of Aβ1−42
and Aβ1−40 in the Hippocampus and
Cortex of APP/PS1 Transgenic Mice
Since accumulating evidence indicates that AD mice exhibits
accelerated Aβ production in the brain with increasing age.
Thus, the levels of Aβ contents in the hippocampus and
cortex of mice were subsequently examined using Western
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FIGURE 1 | Effects of ICS II on spatial learning and memory functions in APP/PS1 transgenic mice. (A) The flow chart of animal experiments. (B) The
escape latency of mice to reach the hidden platform from day 1 to day 4. (C) The percent of time that mice swimming in the target quadrant. Values were expressed
as mean ± SEM (WT+NS, n = 9; WT+ICS II 10 mg/kg, n = 10; WT+ICS II 30 mg/kg, n = 10; APP/PS1+NS, n = 12; APP/PS1 + ICS II 10 mg/kg, n = 12;
WT+ICS II 30 mg/kg, n = 13), ∗p < 0.05, ∗∗p < 0.01 vs. WT+NS, #p < 0.05,##p < 0.01 vs. APP/PS1+NS. Abbreviation: SEM, standard error of the mean; NS,
normal saline.
blot. As depicted in Figures 3A–D, the levels of Aβ1−42
(p< 0.001; p< 0.01) [Hippocampus (F(5,12) = 9.007, p< 0.001);
Cortex (F(5,12) = 5.667, p < 0.01)] and Aβ1−40 (p < 0.001;
p < 0.01) [Hippocampus (F(5,12) = 29.012, p < 0.001); Cortex
(F(5,12) = 3.869, p = 0.025)] were markedly enhanced in
APP/PS1 transgenic mice. However, after treated with two doses
of ICS II resulted in a dramatic reduction in both Aβ1−42 and
Aβ1−40 (p < 0.01; p < 0.05) (p < 0.01; p < 0.01). In addition,
ICS II treatment in WT mice did not facilitate the Aβ levels.
Together, these results indicated that long-term ICS II treatment
significantly reduces Aβ1−42 and Aβ1−40 levels.
Effects of ICS II on Process of Aβ
Production in the Hippocampus and
Cortex of APP/PS1 Transgenic Mice
Abnormally increased Aβ production closely correlates with the
secretases of APP cleavage process, therefore we next assessed the
process of APP changes which could contributes to the decreased
Aβ production. As showed in Figures 4A–L, quantitative analysis
results indicated significant differences in the protein level of
APP in APP/PS1 model group compared with WT control
group (p < 0.01; p < 0.01) [Hippocampus F(5,12) = 10.670,
p < 0.001; Cortex F(5,12) = 20.739, p < 0.001] (Figures 4B,J).
Moreover, chronic treatment with ICS II significantly suppressed
the APP level in a concentration dose-dependent manner
(p < 0.01; p < 0.05). Because two key enzymes, ADAM10
and BACE1, are involved in the initial cleavage of APP, we
further analyzed the ADAM10, BACE1 protein expressions and
the levels of major APP-cleaved product (sAPPα and sAPPβ).
Quantitative analysis showed that ICS II treatment markedly
increased the level of sAPPα [Hippocampus F(2,6) = 7.515,
p = 0.023 and Cortex F(2,6) = 18.272, p = 0.003] (p < 0.01;
p < 0.01) and decreased the level of sAPPβ [Hippocampus
F(2,6) = 7.662, p = 0.022 and Cortex F(2,6) = 46.559,
p < 0.001] (p < 0.05; p < 0.01) in APP/PS1 control group.
However, the dose of 10 mg/kg ICS II did not change the
levels of sAPPα in the hippocampus (p = 0.183) and cortex
(p= 0.242).
Moreover, in the APP/PS1 transgenic mice, the ADAM10
level was dramatically reduced relative to WT control
group [Hippocampus F(5,12) = 5.177, p = 0.009 and Cortex
F(5,12) = 8.221, p = 0.001] (p < 0.01; p < 0.01) (Figures 4D,I).
In contrast, the protein levels of BACE1 were clearly enhanced
(p< 0.01; p< 0.01) [Hippocampus F(5,12) = 4.427, p< 0.05 and
Cortex F(5,12) = 9.304, p < 0.01] (Figures 4F,L). Interestingly,
ICS II (30 mg/kg) could also blunt the down-regulation of
ADAM10 (p< 0.01; p< 0.01). ICS II (10, 30 mg/kg) significantly
down-regulated the BACE1 protein levels (p < 0.05; p < 0.01)
and no differences were found among the WT animals. These
results may suggest that ICS II inhibited Aβ production via
reducing the protein expression of APP and BACE1 and
inducing ADAM10 protein expression in APP/PS1 transgenic
mice.
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FIGURE 2 | Effects of ICS II on neuronal cells and senile plaque formation in the hippocampus of APP/PS1 transgenic mice. (A) Representative
photomicrographs of Nissl staining results of each group (magnification 400×, scale bar = 50 µm). (B,C) Statistics of viable neurons in the hippocampal CA3 and
DG regions. (D) Images of thioflavine S-stained senile plaques results of each group (magnification 40×, scale bar = 200 µm). (E,F) Statistics of thioflavine S-stained
amyloid burden and amyloid plaques number in the hippocampus. Values were expressed as mean ± SEM (n = 3 each), ∗p < 0.05, ∗∗p < 0.05 vs. WT+NS,
#p < 0.05, ##p < 0.01 vs. APP/PS1+NS. SEM, standard error of the mean; NS, normal saline.
The Inhibition of eIF2α and PERK
Phosphorylation Mediated Pathway and
Suppression of PPARγ Degradation Were
Involved in the ICS II-Reduced BACE1
Effect in APP/PS1 Transgenic Mice
Phosphorylation eIF2α/PERK and PPARγ are important
signaling pathway could regulate BACE1 levels. Thus, we
next examined whether ICS II could inhibited the level of
p-eIF2α or p-PERK in the brains of APP/PS1 transgenic
mice (Figures 5A,B). The levels of p-eIF2α[Hippocampus
F(5,12) = 5.632, p = 0.007; Cortex F(5,12) = 5.597,
p = 0.007] (p < 0.01; p < 0.001) and p-PERK (p < 0.01;
p < 0.05) [Hippocampus F(5,12) = 10.561, p < 0.001; Cortex
F(5,12) = 2.743, p = 0.071] in APP/PS1 transgenic mice both
were much higher than WT control group (Figures 5C,D),
which is in agreement with previous studies and also consistent
with the results of BACE1 level. Chronic ICS II (30 mg/kg)
treatment significantly inhibited the levels of p-eIF2α (p < 0.01;
p < 0.05) and p-PERK (p < 0.01; p < 0.05). The results
further support the notion that ICS II has neuroprotective
effect in APP/PS1 transgenic mice and that the mechanisms
may involve the reduction of BACE1 via dephosphorylation
of eIF2α/PERK. Another transcription factor, PPARγ, can
regulate BACE1 activity and reduce Aβ production. Here, we
also examined the PPARγ level in the hippocampus and cortex
of APP/PS1 transgenic mice (Figures 5A,B). As compared
to WT control group, APP/PS1 transgenic mice exhibited a
lower level of PPARγ in different brain regions (p < 0.01;
p < 0.01) [Hippocampus F(5,12) = 7.045, p = 0.003; Cortex
F(5,12) = 10.064, p = 0.001] (Figure 5E). It is therefore possible
that at least part of the activation of PPARγ expression was
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FIGURE 3 | Effect of ICS II on the levels of Aβ1−42 and Aβ1−40 in the hippocampus and cortex of APP/PS1 transgenic mice. (A,B) The antibody-reactive
bands of Aβ1−42 and Aβ1−40 in the hippocampus and cortex of different groups. (C) Quantitative analysis of Aβ1−42 levels. (D) Quantitative analysis of Aβ1−40 levels.
The relative optical density was normalized to β-actin. Data are presented as mean ± SEM (n = 3 each), ∗∗p < 0.01 vs. WT+NS, #p < 0.05,##p < 0.01 vs.
APP/PS1+NS. SEM, standard error of the mean; NS, normal saline; Aβ, Amyloid-β.
related to the level of BACE1, which could contribute to
suppression of Aβ production.
Effects of ICS II on Protein Levels of
PDE5A in the Hippocampus and Cortex
of APP/PS1 Transgenic Mice
The PDE5A level was also measured in the hippocampus and
cortex of APP/PS1 transgenic mice by using the PDE51 antibody
(p < 0.01, p < 0.05). Following ICS II treatment for 3 months,
a markedly reduced PDE5A level was seen in the hippocampus
and cortex with a dose-dependent manner [Hippocampus
F(5,12) = 4.261, p < 0.05 and Cortex F(5,12) = 4.806, p < 0.05]
(p < 0.05, p < 0.05) (Figures 6A–C). This result clearly
demonstrated that the overexpression level of PDE5A in
hippocampus and cortex of APP/PS1 transgenic mice could be
attenuated by ICS II.
DISCUSSION
This study demonstrated that ICS II protected against spatial
learning and memory impairments, decreased senile plaque and
Aβ levels, and promoted viable neuron as well as inhibited PDE5
in APP/PS1 transgenic mice.
Although AD is a multifactor disease that the exact
pathogenesis is not fully clarity, multiple lines of studies
demonstrate that Aβ aggregation in the brain is key factor for
the development of AD (Sun et al., 2015; Sengupta et al., 2016).
APP/PS1 transgenic model mouse is widely applied to many
studies of AD that possesses the overexpression of human APP
encoding gene and PS1 gene mutations, and which are related
to the familial early-onset AD (Bilkei-Gorzo, 2014; Allue et al.,
2016; Choi et al., 2016). In addition, the mouse is not only capable
of modeling some main pathological characteristics of AD via
the excessive accumulation of Aβ, but also the appearance of
senile plaque and cognitive dysfunction (Chin, 2011; Chouraki
and Seshadri, 2014). Therefore, this study used 12-month-old
male APP/PS1 mice to detect the effects of ICS II on cognitive
decline and Aβ production. The MWM test results showed
substantial spatial learning and memory disorder and neuron loss
in APP/PS1 transgenic mice, which are consistent with previous
studies (Zhang et al., 2011; Yang R.Y. et al., 2015). Importantly,
the deficits were effectively restored by chronic treatment with
ICS II.
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FIGURE 4 | Effect of ICS II on process of amyloid-β production in the hippocampus and cortex of APP/PS1 transgenic mice. (A,G) The antibody-reactive
bands of APP, sAPPα, and ADAM10 as well as sAPPβ and BACE1 in the hippocampus and cortex of different groups. (B,J) Quantitative analysis of APP protein
expression. (C,H) Quantitative analysis of sAPPα protein expression. (E,K) Quantitative analysis of sAPPβ protein expression. (D,I) Quantitative analysis of ADAM10
protein expression. (F,L) Quantitative analysis of BACE1 protein expression. The relative optical density was normalized to β-actin. Data are presented as
mean ± SEM (n = 3 each), ∗∗p < 0.01 vs. WT+NS, #p < 0.05,##p < 0.01 vs. APP/PS1+NS. SEM, standard error of the mean; NS, normal saline; APP, amyloid
precursor protein; sAPPα, soluble APP-α; sAPPβ, soluble APP-β; BACE1, β-site APP cleavage enzyme 1; ADAM10, a disintegrin and metalloproteinase domain 10.
PDE5 is a 3′, 5′ cyclic guanosine monophosphate hydrolase
(Garcia-Osta et al., 2012). Clinically, PDE5-Is are used for
treating secondary pulmonary hypertension (Das et al., 2015),
and there are recent emerging interests in its role on
neurodegenerative diseases (Garcia-Osta et al., 2012). A series of
previous evidence indicates that PDE5-Is could improve memory
performance in animal models of AD via suppressing the levels
of Aβ contents (Zhang et al., 2013b) and inhibiting the effect of
induced neuronal loss (Yin et al., 2016). It also shows beneficial
effects on amyloid deposition (Puzzo et al., 2009). Recently, we
found that ICS II as a PDE5-I protects against H2O2-induced
PC12 cells death and attenuates STZ-induced cognitive deficits
in rats (Yin et al., 2016; Gao et al., 2017). In this present study,
the increased protein expression of PDE5 was found in the
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FIGURE 5 | Effects of ICS II on the PPARγ expression and the phosphorylation levels of eIF2α and PERK in APP/PS1 transgenic mice. (A,B) The
antibody-reactive bands of p-eIF2α, p-PERK, and PPARγ in the hippocampus and cortex of different groups. (C) Quantitative analysis of p-eIF2α levels.
(D) Quantitative analysis of p-PERK levels. The relative optical density was normalized to eIF2α and PERK. (E) Quantitative analysis of PPARγ protein expression.
The relative optical density was normalized to β-actin. Data are presented as mean ± SEM (n = 3 each), ∗p < 0.05, ∗∗p < 0.01 vs. WT+NS, #p < 0.05,##p < 0.01
vs. APP/PS1+NS. SEM, standard error of the mean; NS, normal saline; eIF2α, eukaryotic initiation factor α; PERK, PKR endoplasmic reticulum regulating kinase;
PPARγ, peroxisome proliferator-activated receptor-γ.
brains of APP/PS1 transgenic mice, which is consistent with prior
observations (Zhang et al., 2013a; Jin et al., 2014). Thus, we
speculated that PDE5 might be involved in the pathogenesis of
AD. As expected, ICS II reversed the aberrantly elevated PDE5A
protein expression and competed with the cleaved process of
APP and further prevented the Aβ production, which finally
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FIGURE 6 | Effects of ICS II on the protein expression of PDE5A in the hippocampus and cortex of APP/PS1 transgenic mice. (A,B) The
antibody-reactive bands of PDE5A in the hippocampus and cortex of different groups. (C) Quantitative analysis of PDE5A protein expression. The relative optical
density was normalized to β-actin. Data are presented as mean ± SEM (n = 3 each) ∗p < 0.05, ∗∗p < 0.01 vs. WT+NS, #p < 0.05,##p < 0.01 vs. APP/PS1+NS.
SEM, standard error of the mean; NS, normal saline; PDE5A, phosphodiesterase type 5A.
led to the improvement of the cognitive functions in APP/PS1
transgenic mice. Those results demonstrated that ICS II might
work as a PDE5 inhibitor for improving AD symptoms in this
mouse model. Lamentedly, it is not clear how ICS II regulates the
catalytic activity of PDE5, this effect is necessary to delineate in
future experiment.
Extracellular deposition of senile plaque is widely recognized
to a critical pathological feature of AD (Joshi et al., 2015) and
represents the most significant neuropathological histological
feature of the AD (Nilsson et al., 2013). In the AD patients,
senile plaques were detected in the hippocampus (Sabri et al.,
2015; Witte et al., 2015). Accumulating evidences have shown that
9-month-old APP/PS1 transgenic mice exhibited the formation
of senile plaques which gradually increased with age (Bibari et al.,
2013; He et al., 2014). Thioflavine S staining results showed that
ICS II could efficiently ameliorate the histopathological lesions.
Beta-amyloid peptides are involved in the formation of senile
plaques (Sengupta et al., 2016). The most common Aβ peptides
consist of 39–43 amino acids. There are two major isoforms
of Aβ, soluble Aβ40, and insoluble Aβ42, but the latter peptide
shows more prone to aggregation and stronger neurotoxicity.
A series of studies have elucidated elevated levels of Aβ1−40 and
Aβ1−42 in the model mice of AD, which may be the critical
factor for causing neuronal deficits and inhibiting the long-
term potentiation (LTP) (Zhu et al., 2013; He et al., 2014; Jin
et al., 2014). Furthermore, the levels of Aβ contents correlate
negatively with the spatial learning and memory functions.
Interestingly, the levels of both Aβ contents were potently
inhibited in ICS II-treated APP/PS1 mice and the underlying
mechanisms are involved in regulating the process of APP,
including non-amyloidogenic and amyloidogenic pathways to
preclude the generation of Aβ. APP is a precursor of Aβ-peptides
(Iakoucheva et al., 2016) and is cleaved by two enzymes (β- and
γ-secretases) (Salminen et al., 2013), which are essential steps for
generating pathogenic Aβ peptides (a central component of senile
plaques in AD brains). It should be noted that the majority of APP
is cleaved by α-secretase causing the secretion of sAPPα, an APP
extracellular fragment, and the formation of a membrane-bound
83 amino acid fragment (C83). sAPPα exhibits neuroprotective,
neurotrophic, and neurogenic properties (Nalivaeva et al., 2014).
Moreover, promoting APP α-secretase cleavage is considered as
an approach to decrease the Aβ production, in particular because
a-secretase appears to compete with BACE1 cleavage site (Saftig
and Lichtenthaler, 2015). The balance of α/β-secretases were
broken, which leads to non-amyloidogenic cleavage process is
gradually interrupted and further facilitates Aβ production in
APP/PS1 transgenic mice (He et al., 2014). Several members
of the ADAM family, such as ADAM10 and ADAM9 as
well as ADAM17, are involved in the activity of α-secretase.
Functionally, ADAM10 has neuroprotective and neurotrophic
effects, it was defined as the most important member of ADAMs
family of α-secretase, which is essential for neurogenesis and
development of the embryonic brain (Vassar, 2013; Du et al.,
2016). Therefore, promoting ADAM10 protein expression is
widely considered to be an effective approach for AD treatment,
and the reduced protein expression of ADAM10 has been linked
to the molecular pathogenesis of AD (Saftig and Lichtenthaler,
2015). Our results found that inhibition of ADAM10 led to
abnormal elevation of Aβ contents in vivo. Notably, treatment
with ICS II greatly increased ADAM10 expression in the
hippocampus and cortex in a concentration dose-dependent
manner.
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FIGURE 7 | Overview diagram illustrates the mechanism of ICS II-mediated Aβ production. Aβ is generated from a sequent cleavage of APP by BACE1 and
γ-secretase, ICS II suppressed PPARγ degeneration as well as inhibition of PERK/eIF2α phosphorylation, causing the inhibition of BACE1 and further the inhibition of
Aβ production and senile plaque formation. In addition, ICS II prompted non-amyloidogenic cleavage process via increasing ADAM10 protein expression,
Furthermore, ICS II protected against cognitive deficits may be closely interrelated to inhibition of PDE5.
Previous studies have documented that abnormal protein
expression of APP and BACE1 could facilitate Aβ production
in AD mice and our experiment results agreed with this (Jin
et al., 2014; Li et al., 2015; Du et al., 2016). BACE1 is a type I
transmembrane aspartic protease that is responsible for cleaving
APP at the β-secretase cleavage site to generate sAPPβ and
formation of a 99-amino-acid-long C-terminal membrane-
bound fragment (C99). In addition, BACE1 undergoes several
posttranslational modifications, including phosphorylation,
N-glycosylation and ubiquitination (Sjölander et al., 2010;
Motoki et al., 2012; Vassar et al., 2014). Because of BACE1
prime physiological functions, it has received intensely
attention as a promising novel strategy against AD. It was
proved that the transcription factor with putative binding
sites to be involved in BACE1 expression in AD. eIF2α is an
important signaling pathway that affects cognitive functions.
The phosphorylation level of eIF2α positively correlated with
BACE1 expression level, which can increased the protein
level of BACE1 in 5 × FAD mice (Devi and Ohno, 2012,
2013). Similarly, phosphorylated eIF2α at Ser51 are aberrantly
elevated associated with the degeneration of neurons in AD
patients (Vassar, 2008; Bose et al., 2011). Moreover, PERK
as an eIF2α kinase acts on eIF2α phosphorylation site and
its phosphatase activity has also been closely related to the
increase of BACE1 level (Devi and Ohno, 2014; Yang et al.,
2016). In our study, we also found that BACE1, the levels of
phosphorylated eIF2α and PERK were significantly higher
in APP/PS1 transgenic mice. A progressive enhancement
of eIF2α/PERK phosphorylation is responsible for BACE1
overexpression and eventually up-regulation of Aβ production
in vivo and in vitro (Zhu et al., 2013; Zhang et al., 2016).
If this were the case, then the fact that chronic treatment
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of ICS II reversed the induction of PERK-eIF2α pathway may
further support the potential utility of ICS II in the treatment
of AD. PPARγ is a transcription factor that modulates Aβ
metabolism via inhibiting BACE1 transcription (Katsouri et al.,
2011). Meanwhile, PPARγ signaling pathway is involved in
ameliorating AD pathology along with its anti-inflammatory
activity. Conversely, activation of the inflammatory factors could
reverse activated BACE1 expression and further facilitated Aβ
secretion (Katsouri et al., 2011; Strobel et al., 2015). In addition,
PPARγ enhancement resulted in suppression of APP expression
through promoting ubiquitination of APP and subsequent
degradation in SHSY5YAPP+ cells (Scuderi et al., 2014). In the
present study, we evaluated the expression of PPARγ in vivo.
Similar to previous findings, we found that PPARγ inhibition
could contribute to the elevation of BACE1, which further
aggravated APP-Aβ process, and eventually resulted in neurons
degradation. Remarkably, ICS II could reduce Aβ production
by inducing PPARγ activation, ultimately ameliorating the
impairment of learning and memory functions.
In summary (Figure 7), this study demonstrated that
ICS II as a broad spectrum anti-cancer natural compound
that remarkably ameliorates learning and memory functions
impairment interferes with multiple pathogenic mechanisms,
including decreasing the formation of senile plaque, Aβ
generation and the neuronal degradation in APP/PS1 transgenic
mice. The protective mechanisms are likely attributable to
increased ADAM10 activation and suppression of APP and
BACE1 expression, these effects appear to be due to the inhibition
of PERK/eIF2α/PPARγ signaling pathway. In addition, ICS II
protected against cognitive deficits may be closely interrelated
to inhibition of PDE5A protein. Combined, the findings provide
strong evidence that ICS II may be developed as a potently
promising natural compound candidate for halting progression
of AD. Nonetheless, the selective PDE5A agonists, BrdU
immunohistochemistry and confocal microscopy is under used
to further clarify the exact mechanism of ICS II on AD, and that
will be as the next chapter in this story.
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